Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 5:13:524.
doi: 10.1186/1471-2407-13-524.

Napsin A as a marker of clear cell ovarian carcinoma

Ingiridur Skirnisdottir  1 , Kathrine Bjersand, Helena Akerud, Tomas Seidal
Affiliations

Napsin A as a marker of clear cell ovarian carcinoma

Ingiridur Skirnisdottir et al. BMC Cancer. .

Abstract

Background: Clear cell carcinomas are aggressive tumors with a distinct biologic behaviour. In a genome-wide screening for genes involved in chemo-resistance, NAPA was over-expressed in cisplatin-resistant cells. The NAPA (protein) Napsin A was described to promote resistance to cisplatin by degradation of the tumor suppressor p53.

Methods: Totally 131 patients were included in this study all in FIGO-stages I-II; 16 were clear cell tumors which were compared with 40 Type I tumors and 75 type II tumors according to the markers Napsin A, p21, p53 and p27 and some clinical features. For detection of the markers tissue microarrays and immunohistochemistry were used.

Results: Positivity for Napsin A was detected in 12 (80%) out of the 15 clear cell tumors available for analysis compared with 3 (4%) out of the Type I and II tumors in one group (p<0.001). Differences in p21 status, p53 status, and p21+p53- status were striking when clear cell tumors were compared with Type I, Type II, and Type I and II tumors in one group, respectively. The p21+p53-status was associated to positive staining of Napsin A (p=0.0015) and clear cell morphology (p=0.0003). In two separate multivariate logistic regression analyses with Napsin A as endpoint both clear cell carcinoma with OR=153 (95% C.I. 21-1107); (p<001) and p21+p53- status with OR=5.36 (95% C.I. 1.6-17.5); (p=0.005) were independent predictive factors. ROC curves showed that AUC for Napsin A alone was 0.882, for p21+p53- it was 0.720 and for p21+p53-Napsin A+AUC was 0.795. Patients with clear cell tumors had lower (p=0.013) BMI than Type I patients and were younger (p=0.046) at diagnosis than Type II patients. Clear cell tumors had a higher frequency (p=0.039) of capsule rupture at surgery than Type I and II tumors.

Conclusions: Positivity of Napsin A in an epithelial ovarian tumor might strengthen the morphological diagnosis of clear cell ovarian carcinoma in the process of differential diagnosis between clear cell ovarian tumors and other histological subtypes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Section of ovarian clear cell carcinoma demonstrating strong (+++) Napsin A positivity as granular cytoplasmic staining in the tumor cells.
Figure 2
Figure 2
ROC curve for “Napsin A phenotype”.
Figure 3
Figure 3
ROC curve for “p21 + p53- phenotype”.
Figure 4
Figure 4
ROC curve for concomitant “p21 + p53-Napsin A + phenotype.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, Bell J. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(3):307–311. doi: 10.1016/j.ygyno.2009.10.074. - DOI - PubMed
    1. McCluggage. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogene. Pathology. 2011;43(5):420–432. doi: 10.1097/PAT.0b013e328348a6e7. - DOI - PubMed
    1. Kurman RJ, Shi I-M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433–433. doi: 10.1097/PAS.0b013e3181cf3d79. - DOI - PMC - PubMed
    1. Zannoni GF, Morassi F, Prisco MG, De Stefano I, Vellone VG, Arena V, Scambia G, Gallo D. Clinicopathologic and immunohistochemical features of ovarian clear cell carcinomas in comparison with type I and type II tumors. IntJ Gynecol Pathol. 2012;31(6):507–516. doi: 10.1097/PGP.0b013e3182518557. - DOI - PubMed
    1. Zhao C, Wu L, Barner R. Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support Two related pathways of tumor development. J Cancer Educ. 2011;2:94–106. - PMC - PubMed

Publication types

MeSH terms

Substances